Sugi Predict

Sugi Predict / Compounds / SCHEMBL1855196

SCHEMBL1855196

SCHEMBL1855196

O=C1C=C(c2ccc([N+](=O)[O-])cc2)CC(=O)O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.41
▸ APP P05067 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ NOTUM Q6P988 1/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ PARL Q9H300 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ ACHE P22303 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ GABRP O00591 1/20 0.36
▸ GABRD O14764 1/20 0.36
▸ GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7094507 0.68 CYP11B1 (0.46) APPLMNAMAPTALDH1A1ACHE
SCHEMBL9122080 0.67 APP (0.50) GAAAPPLMNAMAPTCA12
SCHEMBL6423919 0.67 CA1 (0.67) GAAAPPLMNAMAPTCA12
SCHEMBL28198 0.67 CA1 (0.67) GAAAPPLMNAMAPTCA12
SCHEMBL6137177 0.67 GAA (0.43) GAAAPPLMNAMAPTNOTUM
SCHEMBL1066989 0.67 APP (0.54) GAAAPPLMNAMAPTCA12
SCHEMBL29310331 0.66 GAA (0.42) GAAAPPLMNAMAPTNOTUM
Water SCHEMBL28670631 0.65 CA1 (0.64) GAAAPPLMNAMAPTCA12
SCHEMBL28711861 0.65 ALDH1A1 (0.65) APPLMNACA12CA1CA2
SCHEMBL22567 0.65 ALDH1A1 (0.72) APPLMNACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296726-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-03-29 — — US disclosed
US-20150051196-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-02-19 — — US disclosed
US-8895584-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-11-25 — — US disclosed
US-20140243382-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-08-28 — — US disclosed
US-8759347-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 — — US disclosed
US-20130281475-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2013-10-24 — — US disclosed
US-8481564-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2013-07-09 — — US disclosed
US-20110195960-A1 INHIBITORS OF C-FMS KINASE ILLIG CARL R 2011-08-11 — — US disclosed
US-7973035-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2011-07-05 — — US disclosed
EP-2021335-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2011-05-25 — — EP disclosed
EP-2021335-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-02-11 — — EP disclosed
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent ILLIG CARL R 2008-11-06 — — US disclosed
US-7414050-B2 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA, N.V. (BE) 2008-08-19 — — US disclosed
WO-2007124316-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 — — WO disclosed
US-20070249593-A1 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281475-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES GAA 3491/4885APP 1697/4885LMNA 3217/4885
US-20070249593-A1 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, PNCK GAA 2146/4885APP 2140/4885LMNA 3361/4885
US-20150051196-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES GAA 3491/4885APP 1697/4885LMNA 3217/4885
US-20140243382-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES GAA 3491/4885APP 1697/4885LMNA 3217/4885
US-20110195960-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES GAA 3491/4885APP 1697/4885LMNA 3217/4885
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, CAMK4 GAA 3244/4885APP 1745/4885LMNA 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.